Efficacy and safety of sotagliflozin in treating diabetes type 1.

Efficacy and safety of sotagliflozin in treating diabetes type 1.

Expert Opin Pharmacother. 2017 Dec 07;:

Authors: Rendell MS

Abstract
INTRODUCTION: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. Sotagliflozin blocks SGLT2 in the kidneys and SGLT1 in the intestines resulting in reduced early phase glucose absorption and increased blood levels of GLP-1 and PYY. Urinary glucose excretion is lower than with other agents as a result of decreased glucose absorption. The primary development effort to date has been in Type 1 diabetes.
AREAS COVERED: The published information on sotagliflozin is reviewed, along with the recent results of several pivotal Type 1 diabetes trials.
EXPERT OPINION: Sotagliflozin treatment lowers HbA1c and reduces glucose variability, with a trend to less hypoglycemic events. Several other SGLT2 inhibitors have been associated with a tendency to diabetic ketoacidosis (DKA). In the Type 1 trials, sotagliflozin treated individuals experienced DKA at a higher rate than placebo treated patients. An additional safety concern arises from the as yet unknown potential risks in women of child bearing potential. Type 1 diabetes is mainly a disease of young people, including young women contemplating pregnancy in whom diabetic ketoacidosis is of utmost concern. The sotagliflozin development program has now been extended to trials in Type 2 diabetes. In Type 2 diabetes, long term studies will be needed to assess the benefits and risks of the agent in comparison to other currently marketed SGLT2 inhibitors.

PMID: 29212386 [PubMed - as supplied by publisher]

http://ift.tt/2kE5Ue0